Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, January 27th.

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% gain by 2025. Learn more on SRPT stock here.

We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this timeframe, the stock has ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...